Show simple item record

dc.contributor.authorCostopoulos, C.
dc.contributor.authorNiespialowska-Steuden, M.
dc.contributor.authorKukreja, N.
dc.contributor.authorGorog, Diana
dc.date.accessioned2014-04-08T12:30:18Z
dc.date.available2014-04-08T12:30:18Z
dc.date.issued2013-09-10
dc.identifier.citationCostopoulos , C , Niespialowska-Steuden , M , Kukreja , N & Gorog , D 2013 , ' Novel oral anticoagulants in acute coronary syndrome ' , International Journal of Cardiology , vol. 167 , no. 6 , pp. 2449-2455 . https://doi.org/10.1016/j.ijcard.2012.08.014
dc.identifier.issn0167-5273
dc.identifier.otherPURE: 2929248
dc.identifier.otherPURE UUID: 9ae30069-3d25-40bc-9465-ce9e5a82333f
dc.identifier.otherScopus: 84883749171
dc.identifier.urihttp://hdl.handle.net/2299/13305
dc.description.abstractCoronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide with a prevalence that has now reached pandemic levels as a consequence of the rapid modernization of the developing world. Its presentation as an acute coronary syndrome (ACS) is a frequent reason for hospital admission and of profound implications for personal, societal and global health. Despite improvements in the management of ACS with anti-platelet and anticoagulant therapy and revascularization techniques, many patients continue to suffer recurrent ischemic events. The need to reduce future cardiovascular events has led to the development of novel therapies to prevent coronary thrombosis, targeting thrombin-mediated pathways. These include direct Xa inhibitors (apixaban, rivaroxaban and darexaban), direct thrombin inhibitors (dabigatran) and PAR 1 antagonists (vorapaxar and atopaxar). This article critically reviews the comparative mechanisms of action, the risks and benefits, together with the clinical evidence base for the use of these novel oral agents in the management of ACS patients.en
dc.language.isoeng
dc.relation.ispartofInternational Journal of Cardiology
dc.titleNovel oral anticoagulants in acute coronary syndromeen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Postgraduate Medicine
dc.contributor.institutionPostgraduate Medicine
dc.contributor.institutionHealth Services and Medicine
dc.contributor.institutionPharmacology and Clinical Science Research
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.ijcard.2012.08.014
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue
herts.rights.accesstyperestrictedAccess


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record